Pharmaceutical

GRWD-5769 by Grey Wolf Therapeutics for Solid Tumor: Likelihood of Approval

GRWD-5769 by Grey Wolf Therapeutics for Solid Tumor: Li...

Nov 2, 2023

GRWD-5769 is under clinical development by Grey Wolf Therapeutics and currently ...

APVO-436 by Aptevo Therapeutics for Myelodysplastic Syndrome: Likelihood of Approval

APVO-436 by Aptevo Therapeutics for Myelodysplastic Syn...

Nov 2, 2023

APVO-436 is under clinical development by Aptevo Therapeutics and currently in P...

PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likelihood of Approval

PRT-811 by Prelude Therapeutics for CNS Lymphoma: Likel...

Nov 2, 2023

PRT-811 is under clinical development by Prelude Therapeutics and currently in P...

Bezuclastinib by Cogent Biosciences for Systemic Mastocytosis: Likelihood of Approval

Bezuclastinib by Cogent Biosciences for Systemic Mastoc...

Nov 2, 2023

Bezuclastinib is under clinical development by Cogent Biosciences and currently ...

Rituximab biosimilar by Celltrion for Waldenstrom Macro...

Nov 2, 2023

Rituximab biosimilar is under clinical development by Celltrion and currently in...

Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: Likelihood of Approval

Gebasaxturev by Merck for Oral Cavity (Mouth) Cancer: L...

Nov 2, 2023

Gebasaxturev is under clinical development by Merck and currently in Phase II fo...

ALG.APV-527 by Alligator Bioscience for Solid Tumor: Likelihood of Approval

ALG.APV-527 by Alligator Bioscience for Solid Tumor: Li...

Nov 2, 2023

ALG.APV-527 is under clinical development by Alligator Bioscience and currently ...

New antibiotic targets gonorrhea as well as last existing treatment, study shows

New antibiotic targets gonorrhea as well as last existi...

Nov 1, 2023

An important Phase 3 trial has shown that a new drug that targets gonorrhea work...

STAT+: After Sarepta trial failure, families and doctors brace for another debate on Duchenne therapy

STAT+: After Sarepta trial failure, families and doctor...

Nov 1, 2023

Sarepta Therapeutics celebrated the results of a clinical trial of its Duchenne ...

STAT+: New insights into how tumor cells hijack brain plasticity to drive cancer

STAT+: New insights into how tumor cells hijack brain p...

Nov 1, 2023

The idea that cancer cells can hijack brain plasticity — subverting healthy brai...

STAT+: Nostrum Labs and its CEO — who once defended Shkreli price hikes — to pay up to $50 million over Medicaid rebates

STAT+: Nostrum Labs and its CEO — who once defended Shk...

Nov 1, 2023

A drugmaker and its chief executive — who once defended Martin Shkreli for raisi...

American Cancer Society expands lung cancer screening guidelines for cigarette smokers

American Cancer Society expands lung cancer screening g...

Nov 1, 2023

No matter how long it was since the last cigarette, the American Cancer Society ...

Infant mortality in the U.S. rose last year for the first time in two decades, says CDC

Infant mortality in the U.S. rose last year for the fir...

Nov 1, 2023

The U.S. infant mortality rose 3% last year, marking the first statistically sig...

STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle cell therapy is safe enough for patients; U.K. is urged to scrap IP demands in trade talks with India

STAT+: Pharmalittle: Panel tells FDA that CRISPR sickle...

Nov 1, 2023

The U.K. government is being urged to scrap intellectual property demands in its...

Gene editing has had a big week in the spotlight. Here’s what’s going on

Gene editing has had a big week in the spotlight. Here’...

Nov 1, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

STAT+: Life science investors close nearly $6 billion in new funds

STAT+: Life science investors close nearly $6 billion i...

Nov 1, 2023

Biotech and life sciences investors continue to draw in new funds even as the bi...